This article is more than 5 years old. Information may no longer be current.
B&L launches Zyoptix in Canada
Click Here to Manage Email Alerts
ROCHESTER, N.Y. — Bausch & Lomb (NYSE: BOL) has begun selling its Zyoptix (Infinity) in Canada. Zyoptix is the company's personalized laser vision correction system. According to B&L executives, the Zyoptix system is the first to integrate both topographic and wavefront diagnostic information for personalized laser vision correction.
Early results from the first Zyoptix systems used commercially in Europe indicate that patients treated with Zyoptix appear to have improved results compared with the company's current LASIK Planoscan laser.
The Zyoptix commercial data shows that at the 1 month visit, 47% of eyes had a 1-line to 2-line improvement in best corrected visual acuity (BCVA). At 3 months, this increased to 55% of patients with a 1-line to 2-line gain in BCVA.
At the 1-month follow-up, the data from the Zyoptix commercial sites indicated that the average postop uncorrected visual acuity was equivalent to the preoperative BCVA.
Zyoptix is composed of two distinct portions: a wavefront analysis device (Zywave) coupled with an advanced corneal mapping system (Orbscan II). Surgeons are able to individually tailor treatments for their patients in a manner they could not previously do, say Bausch & Lomb executives.
"Unlike any other LASIK technology, the Zyoptix system for personalized vision correction takes into account the eye's complete optical system to deliver the most precise procedure and clinical outcome," said Gordon Balazsi, MD, of the Laservue Eye Centre in Montreal.
For more information, go to www.bausch.com.